R&D Bioanalytical labs need to reimagine data to streamline thei... The fundamental questions in the trial phases of drug development are “Does it work?”, “Is it safe?”, and “What else do we need to know?”
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.